We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GENERICS MAY DELETE USE LISTING ON SKELAXIN LABELING, FDA SAYS
GENERICS MAY DELETE USE LISTING ON SKELAXIN LABELING, FDA SAYS
March 23, 2004
Generic firms seeking to market a version of King Pharmaceuticals’ muscle relaxant Skelaxin (metaxalone) are not required to list some prescribing information on the product’s label, said the FDA in a decision that clears a roadblock to generic competition.